ImmunoPhotonics Patent Portfolio Analysis

Ten million against a 2013 priority

A $10M Series C from Cultivation Capital, Arch Grants and iSelect Fund. The company was founded in 2008. The first patent family dates to 2013. That is a long runway before this round, and it means the money is arriving on top of a filing record rather than in place of one.

The last public filing sits 48 months before the raise. Anything filed since is still inside the eighteen month publication window and invisible from outside. So the portfolio a reader can inspect today is a snapshot taken four years ago, and the question is whether that snapshot is the whole picture or the beginning of one.

Four solid ticks, four still thin

Eight families since 2013. Four granted, four published and pending, with the first of the pending group close enough to grant that the arc could thicken without warning. Filings appear in CN, EP, KR, US and WO, which is a deliberate spread rather than a domestic filing that later drifted abroad.

The velocity tells its own story. One family in 2013, then nothing until 2018. One that year, two in 2019, one in 2021, then three in 2022. The recent titles are chitosan-derived compositions and, twice over, methods for producing glycated chitosans. The late burst is not about new indications. It is about manufacture.

The 2022 filings are process chemistry, not therapy.

One name on every single family

Thirty-four inventors are named across the portfolio. Joseph Raker appears on eight of eight. Tomas Hode and Luciano Alleruzzo each appear on seven. That is a dense core with a wide collaborative edge, the shape you get when a small technical group runs the invention and pulls in specialists per family.

A perfect eight-of-eight attendance record over nine years is unusual. It means the technical thread has not been handed off, reworked by a successor team, or split between two programmes. Whatever coherence the claims have across compositions and production methods, it traces back through one person who was present at every filing decision.

Eight ticks beside three hundred circles

The same CPC groups drew University of California with 390 families over five years, China Pharma University with 285, Inst Nat Sante Rech Med with 275, University of Texas with 262, Novartis with 222 and Centre Nat Rech Scient with 206. On that scale eight is a dot. A61K medicinal preparations is one of the most heavily worked classifications there is.

Count is the wrong measure here. In a crowded class, the only thing that separates a family from the surrounding volume is what the claims actually cover. The second cluster is the interesting one: C08B, polysaccharide chemistry. That is not where oncology portfolios usually sit, and it narrows the field considerably.

In a class this dense, scope is the only currency.

Who has read this file already

Histosonics cites the portfolio across eleven publications. University of Michigan cites it seven times. Lytix Biopharma As and Forty Seven cite it three times each, and Nordquist Robert twice. Citation is not endorsement, but it is evidence that the work sits on a path other groups are walking, and that examiners keep finding it relevant.

The mix matters. A device-focused organisation, a research university and two biotechs all landed on the same eight families. That suggests the underlying chemistry is useful across delivery approaches rather than tied to one modality, which is what you would expect if the defensible asset is the material and how it is made.

What the file says it protects

The company says it develops immunotherapy-based treatments for cancer. The file says something more specific. Three of the last four filings are methods for producing glycated chitosans. The claims cluster in A61K and C08B together. Four families are granted and therefore enforceable today, and a fifth is close.

That is a manufacturing moat wearing a therapeutics label. It is thin by count and it sits in a class dominated by institutions filing two hundred families a year. But it is narrow, it is coherent, one inventor has carried it since 2013, and the newest work is about how to make the molecule rather than what to call it.